Provention Bio, Inc., (NASDAQ: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

Provention Bio Announces Pricing of $40 Million Public Offering of Common StockSeptember 18, 2019 8:26 PM After-Hours Movers 09/18: (MDR) (CBPO) (SPLK) Higher; (VBIV) (PRVB) (X) Lower (more...)September 18, 2019 6:08 PM Provention Bio Inc. (PRVB) Plans Public Offering of Common StockSeptember 18, 2019 4:14 PM